Glucocorticoids mediate muscle atrophy in many catabolic states. Myostatin expression, a negative regulator of muscle growth, is increased by glucocorticoids and myostatin overexpression is associated with lower muscle mass. This suggests that myostatin is required for the catabolic effects of glucocorticoids. We therefore investigated whether myostatin gene disruption could prevent muscle atrophy caused by glucocorticoids. Male myostatin knockout (KO) and wild-type mice were subjected to dexamethasone treatment (1 mg/kg⅐d for 10 d or 5 mg/kg⅐d for 4 d). In wild-type mice, daily administration of lowdose dexamethasone for 10 d resulted in muscle atrophy (tibialis anterior: ؊15%; gastrocnemius: ؊13%; P < 0.01) due to 15% decrease in the muscle fiber cross-sectional area (1621 ؎ 31 vs. 1918 ؎ 64 m 2 , P < 0.01). In KO mice, there was no reduction of muscle mass nor fiber cross-sectional area after dexamethasone treatment. Muscle atrophy after 4 d of high-dose dexamethasone was associated with increased mRNA of enzymes involved in proteolytic pathways (atrogin-1, muscle ring finger 1, and cathepsin L) and increased chymotrypsin-like proteasomal activity. In contrast, the mRNA of these enzymes and the proteasomal activity were not significantly affected by dexamethasone in KO mice. Muscle IGF-I mRNA was paradoxically decreased in KO mice (؊35%, P < 0.05); this was associated with a potentially compensatory increase of IGF-II expression in both saline and dexamethasone-treated KO mice (2-fold, P < 0.01). In conclusion, our results show that myostatin deletion prevents muscle atrophy in glucocorticoid-treated mice, by blunting the glucocorticoid-induced enhanced proteolysis, and suggest an important role of myostatin in muscle atrophy caused by glucocorticoids. (Endocrinology 148: 452-460, 2007) 
C
ATABOLIC CONDITIONS ARE associated with hypercortisolism, which in turn plays a major role in skeletal muscle atrophy (1, 2) . Indeed, administration of high doses of glucocorticoids induces muscle atrophy, mainly due to the stimulation of muscle proteolysis (3, 4) . This glucocorticoidinduced protein degradation is mainly mediated by the activation of the ubiquitin-proteasome and lysosomal pathways. In particular, the muscle-specific E3-ligases, atrogin-1 and muscle ring finger 1 (MuRF1), and the lysosomal enzyme cathepsin L are highly stimulated by glucocorticoids (1, 5, 6) . Furthermore, the inhibition of glucocorticoid action by RU486, an antagonist of the glucocorticoid receptor, markedly reduces the loss of muscle mass encountered in several catabolic states (2, 7) .
Myostatin, a member of the TGF-␤ family, is an important negative regulator of skeletal muscle mass (8) . Indeed, targeted disruption of myostatin gene expression in mice leads to dramatic increases in skeletal muscle mass due to muscle fiber hyperplasia and/or hypertrophy (8, 9) . In addition, natural inactivating mutations of the myostatin gene in cattle are associated with a double-muscling phenotype (10 -12) . Conversely, transgenic mice that overexpress myostatin selectively in skeletal muscle have lower muscle mass (13) . All together, these observations indicate that muscle myostatin regulates negatively the skeletal muscle mass.
Dexamethasone-induced muscle atrophy is associated with a dose-dependent marked induction of muscle myostatin mRNA and protein expression (14) . Increased muscle myostatin expression has been also reported in several models of muscle atrophy such as immobilization, microgravity, and burn injuries, in which glucocorticoids play a major role (15) (16) (17) . These observations indirectly suggest that myostatin may play a crucial role in glucocorticoid-induced muscle loss. However, it is not yet directly established whether the presence of myostatin is required for the expression of the glucocorticoid-induced catabolic effects. Moreover, the potential role of myostatin in the glucocorticoid activation of the components of the ubiquitin-proteasome and lysosomal proteolytic pathways is still unknown.
We therefore investigated whether myostatin gene disruption could prevent muscle atrophy caused by glucocorticoids and whether this protective effect may result from down-regulation of the ubiquitin-proteasome and lysosomal pathways. and 8-wk-old wild-type (WT) male FVB mice (n ϭ 28 WT mice) provided by Janvier Breeding (Le-Genest-Saint-Isle, France) were used to assess the role of myostatin in the muscle atrophy caused by glucocorticoids. The animals were housed individually under controlled conditions of lighting (12-h light, 12-h dark cycle) and temperature (22 Ϯ 2 C). All animals were allowed to free access to chow and water. Body weight was measured daily. The study was conducted in accordance with the directives of the Institutional Animal Care and Use Committee of the University of Louvain.
Experimental design
After 1 wk adaptation to environment and diet, KO as well as WT mice were randomly allocated to one of four treatment groups. Two groups were injected with dexamethasone, whereas the two others were injected with saline. The saline groups received a daily sc injection of saline solution (vehicle, 0.9% NaCl). The glucocorticoid-treated groups received a daily sc injection of saline solution of dexamethasone (Aacidexam; Organon, Oss, The Netherlands), at either 1 mg/kg⅐d (low dose) or 5 mg/kg⅐d (high dose). Mice injected with the high and low dose and their corresponding control groups were killed by decapitation, respectively, after 4 and 10 d of dexamethasone treatment. For biochemical analysis, gastrocnemius muscles were removed, weighted, deep frozen in liquid nitrogen, and stored at Ϫ80 C until further analysis. For histological analysis, tibialis anterior muscles were dissected, weighed, and a transversal slice of 0.5 cm thickness was made in the middle belly of the muscle. This slice was embedded in Tissue Tek (Sakura, Zoeterwoude, The Netherlands), frozen in precooled isopentane, and stored at Ϫ80 C until further analyzed. The morphological analyses and protein measurements were performed on samples collected at d 10 and the biochemical analyses were obtained from muscles collected at d 4.
Muscle protein extraction
Briefly, 100 mg of whole gastrocnemius muscle, previously pestled in liquid nitrogen, were homogenized with Ultraturrax (IKA-Labortechnik, Staufen, Germany) in 1 ml ice-cold lysis buffer [50 mm Tris/HCl (pH 7.5), 1 mm EDTA, 1 mm EGTA, 0.5% Nonidet P-40, 1 mm phenylmethylsulfonylfluoride, 10 g/ml aprotinin, 10 g/ml leupeptin, 10 mm ␤-glycerophosphate, 1 mm KH 2 PO 4 , 1 mm vanadate, 50 mm NaF, 10 mm NaPPi]. Homogenates were centrifuged 10 min at 10,000 rpm (Sorvall SS-34 rotor) to pellet myofibrillar proteins. Myofibrillar proteins, resuspended in 8 m urea per 50 mm Tris/HCl (pH 7.5), were stored at Ϫ80 C as well as the supernatant containing the soluble proteins. Myofibrillar and soluble muscle protein concentrations were determined using Bradford's protein assay (Bio-Rad, Munich, Germany).
Peptidase activities of the 20S proteasome
Proteolytic activities of the 20S proteasome were measured on individual gastrocnemius muscles collected after 4 d of treatment with dexamethasone 5 mg/kg⅐d, as previously described (18) . One hundred milligrams of skeletal muscles from WT and KO mice treated or not with dexamethasone were homogenized in ice-cold buffer (pH 7.5) containing 50 mm Tris, 250 mm sucrose, 10 mm ATP, 5 mm MgCl 2 , 1 mm dithiothreitol (DTT), and protease inhibitors (10 g/ml antipain, aprotinin, leupeptin, and pepstatin A and 20 m phenylmethylsulfonyl fluoride). The proteasomes were isolated by three sequential centrifugations. The final pellet was resuspended in buffer containing 50 mm Tris (pH 7.5), 5 mm MgCl 2 , and 20% glycerol. The protein content of the proteasome preparation was determined according to Lowry et al. (42) . Peptidase activities of the proteasome were determined by measuring the hydrolysis of the fluorogenic substrates Succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin (LLVY) and Boc-Leu-Arg-Arg-7-amido-4-methylcoumarin (LRR). These substrates are preferentially hydrolyzed by the chymotrypsin-like and the trypsin-like peptidase activities of the proteasome, respectively.
To measure peptidase activity, 15 l of the proteasome extract were added to 30 l of preincubation medium containing 50 mm Tris (pH 8.0), 12.5 mm MgCl 2 , 1.5 mm DTT, 0.012 U/l apyrase, and Ϯ 66.6 m MG132 and preincubated 15 min at room temperature to allow complete inhibition of the proteasome. Then 30 l of the reaction buffer containing 50 mm Tris (pH 8.0), 10 mm MgCl 2 , 1 mm DTT, 0.008 U/l apyrase, and 750 m LLVY or 2 mm LRR were added to the 45 l of the preincubation reaction so that final concentrations were as follows: 300 m LLVY-AMC or 800 m LRR-AMC and 40 m MG132. The peptidase activity was determined by measuring the accumulation of the fluorogenic cleavage product [methylcoumaryl-amide (MCA)] using a luminescence spectrometer FLX800 (Biotek, Winsookie, VT). Fluorescence was measured continuously during 45 min at 380 nm (MCA) excitation wavelength and 440 nm (MCA) emission wavelength. The difference between arbitrary fluorescence units recorded with or without 40 m of the proteasome inhibitor MG132 (Affiniti, Golden, CO) in the reaction medium was calculated, and the final data were corrected by the amount of protein in the sample. The time course for the accumulation of MCA after hydrolysis of the substrate was analyzed by linear regression to calculate peptidase activities, e.g. the slopes of best fit of accumulated MCA vs. time. Different kinetics were performed to measure individually the two proteasome peptidase activities.
RNA extraction and analysis by real-time quantitative (RTQ)-PCR
Total RNA was isolated from the gastrocnemius muscle using TRIzol reagent as described by the manufacturer. Recovery was 1 g/mg gastrocnemius. Reverse transcriptase using 1 g of total RNA was done as previously described (19) . Specific primers were determined using the Primer Express software (Applied Biosystems, Foster City, CA). Accession number for the sequences and primers used were: IGF-I, NM184052 (GCTATGGCTCCAGCATTCG-TCCGGAAGCAACACTCATCC); IGF-II, NM031511 (GTCGATGTTGGTGCTTCTCATCT-CGGTCCGAACA-GACAAACTGAA); myostatin, AY204900 (GGCTTGACTGCGATGA-G-ATATAGCATATTAATGGGAGACAT); atrogin-1, AF441120 (AGC-GACCTCAGCAGTTACTGC-CTTCTGGAATCCAGGATGGC); Mu-RF1: AF294790 (TGTCTGGAGGTCGTTTCCG-ATGCCGGTCCATGA-TCACTT); cathepsin L, NM009807 (CTCATGAAGGCTGTGGCGA-A-ACTGGAGAGACGGATGGCTT); forkhead box class O (FOX) O3a, NM019740 (TCGTCTCTGAACTCCTTGCGT-TGGAGTGTCTGGTTG-CCGT); and glyceraldehyde-3-phosphate dehydrogenase, AF106860 (T-GCACCACCAACTGCTTA-GGATGCAGGGATGATGTTC) used as reporter gene. Primers were tested to avoid primers dimers, selfpriming formation, or unspecific amplification. Primers were designed to have standardized optimal PCR conditions.
RTQ-PCR was carried out using following cycle parameters: 10 min at 95 C, followed by 40 cycles of 1 min at 60 C and 15 sec at 95 C. For each gene, RTQ-PCR was conducted in duplicate with 25 l reaction volume of 1 ng cDNA. To ensure the quality of the measurements, each plate included for each gene a negative control and a positive control. Results were expressed using the comparative cycle threshold (Ct) method as described in the user bulletin no. 2 (Applied Biosystems). Briefly, the ⌬Ct values were calculated in every sample for each gene of interest as followed: Ct gene of interest Ϫ Ct reporter gene with glyceraldehyde-3-phosphate dehydrogenase as the reporter gene. The calculation of the relative changes in the expression level of one specific gene (⌬⌬Ct) was performed by subtraction of the ⌬Ct from the control group to the corresponding ⌬Ct from the treated groups (19, 20) The values and ranges given in different figures were determined as followed: 2 Ϫ⌬⌬Ct with ⌬⌬Ct ϩ sem and ⌬⌬Ct Ϫ sem, where sem is the sem of the ⌬⌬Ct value (user bulletin no. 2; Applied Biosystems).
Histological analysis of muscle
Cryostat serial sections (10 m thick) were obtained and mounted onto glass slides. The sections were fixed 2 min with acetone for hematoxylin-eosin staining. Muscle and fiber cross-sectional area (CSA) were measured with a microscope (Leitz, Wetzlar, Germany) coupled to an image analyzer system (Kontron image analysis division MOPVideoplan, Eching, Germany). To evaluate muscle fiber CSA, 200 fibers were randomly chosen and counted per muscle.
Statistical analysis
Results are presented as means Ϯ sem. Interaction between the glucocorticoids and the absence of myostatin was assessed by using twoway ANOVA followed by a Bonferroni posttest using GraphPad Prism (version 4.00 for Windows; GraphPad Software, San Diego, CA). Fiber CSA distribution statistical analysis was performed using 2 Pearson test. Statistical significance was set at P Ͻ 0.05.
Results

Animal weight
Baseline body weights were 6% higher in KO than WT mice (P Ͻ 0.01). Body weight remained stable over 10 d in saline-injected WT and KO mice (Fig. 1) . Dexamethasone administration, at the low dose, caused a progressive decline in body weight of WT mice, which was already significant (P Ͻ 0.05) at d 1. At the end of the 10 d of dexamethasone treatment, body weight decreased by 5% vs. baseline (P Ͻ 0.05). In contrast, no detectable decrease in body weight was observed in dexamethasone-injected KO mice after 10 d. The high dose of dexamethasone decreased the body weight in both groups, the effect being slightly more pronounced in WT than KO mice (Ϫ5.3%, P Ͻ 0.01 and Ϫ2.7%, P Ͻ 0.05 after 4 d, respectively, interaction genotype * treatment: P ϭ 0.08).
Muscle weight
Deletion of myostatin in mice led to excessive muscle growth, as illustrated by a large increase in skeletal muscle mass (tibialis anterior: ϩ62%, P Ͻ 0.001; gastrocnemius: ϩ47%, P Ͻ 0.001; soleus: ϩ41%, P Ͻ 0.001 vs. WT mice) (Fig.  2) .
After 10-d dexamethasone treatment, the tibialis anterior and gastrocnemius muscle weights were significantly lower in WT mice injected with the low dose of dexamethasone, compared with their controls injected with saline (Ϫ15 and Ϫ13%, respectively, P Ͻ 0.01). Soleus muscle weight was not significantly affected by dexamethasone, although the same tendency was observed (Ϫ11%, P Ͼ 0.05). By contrast, in the KO mice, no reduction of muscle mass was observed after the low-dose dexamethasone treatment (tibialis anterior: ϩ2%, P Ͼ 0.05; gastrocnemius: Ϫ3%, P Ͼ 0.05; soleus: ϩ12%, P Ͼ 0.05). The effects of 4 d treatment with the high dose of dexamethasone were similar to those observed after 10 d treatment with the low dose (WT mice: tibialis anterior, Ϫ13%, P Ͻ 0.01; gastrocnemius, Ϫ14%, P Ͻ 0.01; soleus, Ϫ11%, P Ͼ 0.05, and KO mice: tibialis anterior, ϩ5%, P Ͼ 0.05; gastrocnemius, Ϫ3%, P Ͼ 0.05; soleus, ϩ4% P Ͼ 0.05) (Fig.   3 ). These data suggest that KO mice are protected against the muscle loss induced by dexamethasone.
Muscle fiber CSA
The histomorphological analysis of the tibialis anterior showed that the increased muscle mass observed in the KO mice results from hyperplasia, but no effect on fiber size (hypertrophy) could be detected. Indeed, the total muscle area was largely increased in the KO mice, compared with WT (10.57 Ϯ 0.54 vs. 6.40 Ϯ 0.3 mm 2 , P Ͻ 0.001), whereas the muscle fiber CSA was similar in the two groups (KO: 1878 Ϯ 74 vs. WT: 1918 Ϯ 64 m 2 , P Ͼ 0.05). As shown in Fig. 4A , the muscle loss induced by dexamethasone in the WT mice was due to a decrease of 15% of the mean muscle fiber CSA (1621 Ϯ 31 vs. 1918 Ϯ 64 m 2 , P Ͻ 0.01). By contrast, dexamethasone treatment did not reduce the muscle fiber CSA in the KO mice (1898 Ϯ 34 vs. 1878 Ϯ 74 m 2 , P Ͼ 0.05). We also compared the fiber size distribution of the tibialis anterior in WT and KO mice injected with dexamethasone or saline. In the WT mice, dexamethasone clearly increased the proportion of fibers of small size (P Ͻ 0.001) (Fig. 4B) . This was in contrast with the observation that in KO mice fiber size distribution was unaffected by dexamethasone (P Ͼ 0.05) (Fig. 4C) . These results confirm the fact that the invalidation of the myostatin gene prevents the muscle atrophy caused by the dexamethasone treatment.
Myofibrillar and soluble muscle proteins
Like the muscle weight, the myofibrillar and soluble protein contents were significantly greater in the KO mice, compared with the WT animals (myofibrillar: 16.3 Ϯ 0.6 vs. 11.6 Ϯ 0.3 mg/muscle, P Ͻ 0.001; soluble: 14.2 Ϯ 1.2 vs. 9.0 Ϯ 0.5 mg/muscle, P Ͻ 0.001) (Fig. 5A) . The myofibrillar content was significantly decreased with low-dose dexamethasone in the WT mice (8.9 Ϯ 0.2 vs. 11.6 Ϯ 0.3 mg/muscle, P Ͻ 0.01) but not the KO (16.1 Ϯ 0.6 vs. 16.3 Ϯ 0.6 mg/muscle, P Ͼ 0.05). The muscle soluble protein content did not decrease significantly with dexamethasone in either of the two groups (WT: 7.5 Ϯ 0.4 vs. 9.0 Ϯ 0.5 mg/muscle, P Ͼ 0.05, and KO: 13.3 Ϯ 1.2 vs. 14.2 Ϯ 1.2 mg/muscle, P Ͼ 0.05).
Proteolysis-related gene expression
Glucocorticoids are known to increase the protein degradation in muscle by the activation of the ubiquitin-proteasome and lysosomal proteolytic systems. We therefore investigated in WT and KO mice the expression of atrogin-1, MuRF1, and cathepsin L enzymes involved, respectively, in activation of the ubiquitin-proteasome and lysosomal systems. The mRNA levels of these enzymes were equivalent in saline-injected WT and KO mice, showing that myostatin is not a major regulator of their expression in baseline conditions (Fig. 5B) . Dexamethasone increased the expression of atrogin-1 (ϩ67%, P Ͻ 0.05), MuRF1 (ϩ89%, P Ͻ 0.01), and cathepsin L (ϩ42%, P Ͻ 0.01) in the gastrocnemius muscle of WT mice. In contrast, the mRNA of these enzymes was not significantly affected by dexamethasone in KO mice (atrogin-1: Ϫ14%, P Ͼ 0.05; MuRF1: ϩ36%, P Ͼ 0.05; cathepsin L: Ϫ1%, P Ͼ 0.05). Because the expression of atrogin-1 and cathepsin L is up-regulated by the transcription factor FOXO3a, we also evaluated changes in its gene expression in the four experimental groups. Dexamethasone increased significantly the FOXO3a expression in the WT animals (ϩ96%, P Ͻ 0.01) but not significantly in the KO mice (ϩ39%, P Ͼ 0.05). All together, these data suggest that a lack of response to dexamethasone treatment in several pathways involved in muscle proteolysis is closely associated with absence of myostatin.
Peptidase activities of the 20S proteasome
Proteolytic activities of the 20S proteasome were measured on individual gastrocnemius muscles collected after 4 d of treatment with dexamethasone (5 mg/kg⅐d), according to the methodology previously described (18) . Our results show that dexamethasone treatment increased the chymotrypsinlike activity of the 20S proteasome in WT mice (28.61 Ϯ 1.62 vs. 12.31 Ϯ 1.21 relative fluorescence units (RFU)/min⅐g protein, P Ͻ 0.001) (Fig. 6A) . The baseline chymotrypsin-like activity was higher in KO than WT mice (29.69 Ϯ 2.67 vs. 12.31 Ϯ 1.21 RFU/min⅐g, P Ͻ 0.001). Most importantly, this activity was not stimulated by glucocorticoids in KO mice (25.11 Ϯ 2.11 vs. 29.69 Ϯ 2.67 RFU/min⅐g, P Ͼ 0.05) supporting the concept that myostatin is mandatory to allow the glucocorticoid-induced stimulation of the proteasome. We also measured the trypsin-like activity of the 20S proteasome but failed to show any difference between KO and WT mice after the dexamethasone treatment (WT: 17.86 Ϯ 1.50 vs. 17.91 Ϯ 1.43 RFU/min⅐g, P Ͼ 0.05; KO: 20.86 Ϯ 1.13 vs. 17.48 Ϯ 2.05 RFU/min⅐g, P Ͼ 0.05) (Fig. 6B) . Combined with the data on atrogin-1 and MuRF1, these results strongly suggest that myostatin gene deletion prevents the glucocorticoid-induced muscle atrophy partially at least by inhibition of the ubiquitin-proteasome system.
Growth factors and myostatin gene expression
Because IGF-I is known to possess an inhibitory effect on atrogin-1, MuRF1, and cathepsin L gene expression, we investigated the hypothesis that this growth factor could repress the glucocorticoid-induced activation of these enzymes in KO animals. As expected, dexamethasone reduced expression of IGF-I in WT mice (Ϫ53%, P Ͻ 0.001) (Fig. 7) . Surprisingly IGF-I mRNA was lower in saline-injected KO mice than WT animals (Ϫ35%, P Ͻ 0.05). Given the fact that IGF-II is also able to interact with the IGF-RI receptor, we monitored its expression in both groups. The muscle IGF-II expression was not affected by dexamethasone but strongly stimulated by the absence of myostatin (ϩ104% in salinetreated and ϩ79% in dexamethasone-treated KO mice, respectively, P Ͻ 0.01).
As previously reported, muscle atrophy observed in WT mice treated with dexamethasone was associated with an WT injected with saline. In WT mice (B), the proportion of large fibers was smaller in dexamethasonetreated mice (1 mg/kg⅐d, black box) than saline group (white box). By contrast, in KO mice (C), the fiber CSA was similar in dexamethasone-and saline-treated groups. Statistical analysis was performed using 2 Pearson test. ***, P Ͻ 0.001. increased expression of myostatin (ϩ38%, P Ͻ 0.05 after 4 d). As expected, myostatin expression was not detected in KO mice.
Discussion
Our observations showed that myostatin gene deletion prevents the skeletal muscle atrophy caused by glucocorticoids. Thus, glucocorticoids administration decreased the muscle weight, muscle fiber CSA, and myofibrillar protein content in control WT mice, whereas these catabolic effects were not observed in myostatin KO mice. To our knowledge, this is the first report of the antiatrophic effect of the absence of myostatin in a model of acquired muscle atrophy. The results suggest that muscle myostatin expression is a major player in the atrophic action of glucocorticoids toward muscle.
Increased proteolysis by the ubiquitin-proteasome and lysosomal systems play a major role in glucocorticoid-induced muscle atrophy (1, 5, 6) . Also, recent evidence has been provided that the transcription factor FOXO stimulates the transcription of several components of these systems such as atrogin-1, MuRF1, and cathepsin L and causes muscle atrophy (21, 22) . Given the key role of myostatin in the protection of the muscle from the glucocorticoid-induced atrophy, we attempted to evaluate its possible effect as a down-regulator of these atrogenes. Anticipating early responses, we determined the muscle mRNA content of atrogenes at an early stage treatment (4 d treatment) in mice injected with a high dose of dexamethasone. In this model, we confirmed that glucocorticoids in WT mice increased muscle expression of atrogin-1 and MuRF1, the two ubiquitin-ligases crucial for muscle atrophy (1, 23) , and cathepsin L, a lysosomal enzyme considered an early marker of muscle atrophy (6, 24) . Most importantly, this activation of atrogenes was blunted in the myostatin-disrupted mice, pointing to a key role of this negative growth factor on these two proteolytic pathways. Very recently, using the in vitro approach, McFarlane et al. (25) showed that myostatin increased atrogin mRNA in myotubes. This finding is in agreement with our data demonstrating that myostatin is required for the glucocorticoidinduced activation of this enzyme. The same authors (25) also showed that the effect of myostatin on atrogin is mediated by the activation of FOXO1. In our experiment, we observed that the FOXO3a mRNA is strongly induced by glucocorticoids and that this activation is blunted in KO mice. This suggested that FOXO3a is also involved in the myostatin-mediated changes of atrogin-1. Changes in FOXO3a phosphorylation could not be demonstrated, given the very low expression of the protein in our model.
Early studies have shown that myostatin inhibited protein synthesis (26, 27) . Up to now, an effect on proteolysis has never been proved. Examining the chymotrypsin-like activity of the proteasome, we observed a higher level in KO than WT mice, suggesting some increase in protein degradation. Given the massive increase in muscle mass of KO mice, it could be speculated that this increased proteolysis might be overridden by accelerated protein synthesis. Such large changes in proteolysis and protein synthesis may indicate a turnover more characteristic of an extensive remodeling process than normal growth. This hypothesis would required additional experimental demonstration. We further examined the effect of myostatin gene deletion on glucocorticoidstimulated proteasomal activity. Induction of the chymotrypsin-like activity by glucocorticoids was clearly present in WT mice but was not observed in KO mice. Taken together, our observations showed that the presence of myostatin is mandatory for the induction of the components of the proteolytic pathways and proteasomal activity by glucocorticoids. This concept is directly supported by in vitro data showing that myostatin added directly to myotubes causes their atrophy as well as an induction of components of the proteolytic pathway (25) . Some in vivo data also suggest that high myostatin levels in the circulation obtained by transplantation of CHO cells engineered ex vivo with myostatin cDNA (25, 28) or in the muscle by overexpressing myostatin (13, 25) cause some muscle atrophy. Glucocorticoid-induced muscle atrophy may be related to increased myostatin muscle expression, as we observed with others (14) . An alternate explanation would be that glucocorticoids also act indirectly by relieving a suppressor of myostatin activity, such as follistatin.
The role of IGFs in the muscle hypertrophy observed in myostatin KO mice has not yet been explored, even though these growth factors possess anabolic and anticatabolic effects (29) . Indeed, persistent overexpression of IGF-I in mice results in skeletal muscle hypertrophy (30) . Furthermore, localized IGF-I overexpression by gene electrotransfer in vivo prevents also muscle atrophy caused by glucocorticoids (31) .
Unexpectedly we observed a slight reduction of muscle IGF-I mRNA levels in control KO vs. control WT mice. This decrease in muscle IGF-I mRNA in myostatin KO mice has also been observed by another group using DNA microarray (32) . However, IGF-II mRNA expression was increased in the muscle of myostatin KO mice. This observation is in line of previous publications reporting by other technical approaches (immunohistochemistry and DNA microarray) (32, 33) , an increase in IGF-II mRNA in skeletal muscles of myostatin KO animals. Although this up-regulation of IGF-II in myostatin KO might suggest a direct negative effect of myostatin on this gene, no such evidence is yet available. Our observation of an inverse relationship between myostatin and IGF-II expression is in line with the work of Lalani et al. (15) showing that muscle atrophy induced in the rat by exposure to microgravity was associated with an up-regulation of myostatin and a down-regulation of IGF-II without change in IGF-I. The increased IGF-II expression in myostatin KO mice might contribute to the skeletal muscle hypertrophy of these animals. Indeed, it is possible that IGF-II acts through an interaction with the IGF-RI receptor (34) . Moreover, in a strain of pigs characterized by a nucleotide substitution in intron 3 of the IGF-II gene, muscle IGF-II mRNA levels are increased 3-fold, and this was associated with increased skeletal muscle mass (35) . Persistent overexpression of IGF-II mRNA in dexamethasone-treated KO mice might therefore participate to the antiatrophic effect of the myostatin deletion. It is not excluded that other signaling pathways such as Wnt, recently described to be activated in myostatin KO mice (32) , participate to the dexamethasone resistance of these animals.
The results obtained in this experience contrast with those of McMahon et al. (36) , who showed that myostatin KO mice lose more skeletal muscle mass than WT during hindlimb suspension. Some hypotheses can be raised to explain the absence of the protective effect of the myostatin deletion in this catabolic situation. First, whereas glucocorticoid-induced atrophy affects mainly fast-twitch muscle fibers (myosin heavy chains IIB) (37) , in which myostatin is abundantly expressed (38) , muscle atrophy caused by unloading affects mainly slow-twitch muscle fibers (melanin-concentrating hormone I), in which myostatin is less expressed (38) . These slow-twitch fibers might be therefore less sensitive than the fast twitch to the protective effects of the inhibition of myostatin, explaining the lack of protective response in the unloading model of muscle atrophy. Second, several data suggest that the glucocorticoid-induced muscle atrophy is mediated through the activation of FOXO (21) . We showed that myostatin deletion blunted the FOXO3a gene expression in the dexamethasone-treated mice, consistent with an interaction between myostatin and FOXO regulation. In contrast, hindlimb suspension is thought to be related to the induction of the nuclear factor-B (39) , and it could be hypothesized that this pathway is independent of myostatin expression.
Rodents treated with exogenous glucocorticoids may have reduced food intake. It is therefore possible that reduction in muscle weight caused by dexamethasone may be related
